Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

(2014) Helmut Oettle et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

(2013) O. E. Rahma et al.   ANNALS OF ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer

(2010) Anna Novarino et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)

(2009) W. Koizumi et al.   ANNALS OF ONCOLOGY

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

(2008) Y Yamada et al.   BRITISH JOURNAL OF CANCER

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

(2008) Henry Q. Xiong et al.   CANCER

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

(2008) Chigusa Morizane et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY